Drucken
Artikel, Notizen und Markierungen werden geladen... Bitte um etwas Geduld.

Ordinance
on Clinical Trials
with the exception of
Clinical Trials of Medical Devices1
(Clinical Trials Ordinance, ClinO)

of 20 September 2013 (Status as of 26 May 2022)

1 Amended by Annex 2 No 2 of the O of 1 July 2020 on Clinical Trials with Medical Devices, in force since 26 May 2021 (AS 2020 3033).

Art. 34 Changes

1 Sig­ni­fic­ant changes to an au­thor­ised clin­ic­al tri­al must be au­thor­ised by the Agency be­fore be­ing im­ple­men­ted. Ex­empt from this re­quire­ment are meas­ures which have to be taken im­me­di­ately in or­der to pro­tect the par­ti­cipants.

2 The spon­sor must sub­mit to the Agency any ap­plic­a­tion doc­u­ments spe­cified in An­nex 4 which are af­fected by the change. At the same time, the spon­sor shall provide in­form­a­tion on the reas­ons for the change.

3 The fol­low­ing are con­sidered to be sig­ni­fic­ant changes:

a.
changes to the medi­cin­al product or product un­der Art­icle 2a para­graph 2 TPA, or to its ad­min­is­tra­tion or use;
b.
changes based on new pre­clin­ic­al or clin­ic­al data which may af­fect product safety; or
c.
changes con­cern­ing the pro­duc­tion of the medi­cin­al product or product un­der Art­icle 2a para­graph 2 TPA which may af­fect product safety.

4 The Agency shall reach a de­cision with­in 30 days after re­ceipt of the com­plete ap­plic­a­tion doc­u­ments af­fected by the change. Art­icle 33 ap­plies mu­tatis mutandis.

5 Oth­er changes which af­fect the doc­u­ments sub­mit­ted to the Agency must be no­ti­fied to the Agency as quickly as pos­sible.